Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 270

1.

Medical Devices: Classification and Analysis of Faults Leading to Harms.

Ferner RE, Aronson JK.

Drug Saf. 2019 Nov 5. doi: 10.1007/s40264-019-00879-2. [Epub ahead of print]

PMID:
31691257
2.

A novel approach to support implementation of biosimilars within a UK tertiary hospital.

Saxby K, Sanghvi S, Bodalia PN, Ferner RE, Leandro M, Urquhart R, Sofat R.

Br J Clin Pharmacol. 2019 Oct 29. doi: 10.1111/bcp.14150. [Epub ahead of print]

PMID:
31663154
3.

Drug and therapeutics committees as guardians of safe and rational medicines use.

Sofat R, Cremers S, Ferner RE.

Br J Clin Pharmacol. 2019 Oct 18. doi: 10.1111/bcp.14088. [Epub ahead of print] No abstract available.

PMID:
31625180
4.

Crisis in the supply of medicines.

Ferner RE, Aronson JK, Heneghan C.

BMJ. 2019 Oct 4;367:l5841. doi: 10.1136/bmj.l5841. No abstract available.

PMID:
31585945
5.

Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50.

Dimmitt SB, Stampfer HG, Martin JH, Ferner RE.

Br J Clin Pharmacol. 2019 Oct;85(10):2218-2227. doi: 10.1111/bcp.14033. Epub 2019 Aug 19. Review.

PMID:
31219198
6.

Antithrombotic dose: Some observations from published clinical trials.

Dimmitt SB, Floyd CN, Ferner RE.

Br J Clin Pharmacol. 2019 Oct;85(10):2194-2197. doi: 10.1111/bcp.13968. Epub 2019 Jul 1. Review.

PMID:
31050833
7.

From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.

Ferner RE, Bakker A, Elgersma Y, Evans DGR, Giovannini M, Legius E, Lloyd A, Messiaen LM, Plotkin S, Reilly KM, Schindeler A, Smith MJ, Ullrich NJ, Widemann B, Sherman LS.

Am J Med Genet A. 2019 Jun;179(6):1098-1106. doi: 10.1002/ajmg.a.61112. Epub 2019 Mar 25.

PMID:
30908866
8.

The relationship between antemortem and postmortem morphine concentrations.

Langford NJ, Morley SR, Ferner RE.

Clin Toxicol (Phila). 2019 Dec;57(12):1142-1145. doi: 10.1080/15563650.2019.1591430. Epub 2019 Mar 23.

PMID:
30905172
9.

Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing.

Evans DG, King AT, Bowers NL, Tobi S, Wallace AJ, Perry M, Anup R, Lloyd SKL, Rutherford SA, Hammerbeck-Ward C, Pathmanaban ON, Stapleton E, Freeman SR, Kellett M, Halliday D, Parry A, Gair JJ, Axon P, Laitt R, Thomas O, Afridi S, Ferner RE, Harkness EF, Smith MJ; English Specialist NF2 Research Group.

Genet Med. 2019 Jul;21(7):1525-1533. doi: 10.1038/s41436-018-0384-y. Epub 2018 Dec 7.

PMID:
30523344
10.

Adverse drug reactions.

Ferner RE, McGettigan P.

BMJ. 2018 Nov 6;363:k4051. doi: 10.1136/bmj.k4051. No abstract available. Erratum in: BMJ. 2018 Nov 12;363:k4777.

PMID:
30401691
11.

Preventing Future Deaths from Medicines: Responses to Coroners' Concerns in England and Wales.

Ferner RE, Ahmad T, Babatunde Z, Cox AR.

Drug Saf. 2019 Mar;42(3):445-451. doi: 10.1007/s40264-018-0738-z.

PMID:
30298309
12.

Reliability of functional outcome measures in adults with neurofibromatosis 1.

Mullin RL, Golding JF, Smith R, Williams V, Thomas M, Ferner RE.

SAGE Open Med. 2018 Jul 23;6:2050312118786860. doi: 10.1177/2050312118786860. eCollection 2018.

13.

Prescribing biosimilars.

Aronson JK, Goldacre B, Ferner RE.

BMJ. 2018 Jul 24;362:k3141. doi: 10.1136/bmj.k3141. No abstract available.

PMID:
30042142
14.

2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Fisher MJ, Belzberg AJ, de Blank P, De Raedt T, Elefteriou F, Ferner RE, Giovannini M, Harris GJ, Kalamarides M, Karajannis MA, Kim A, Lázaro C, Le LQ, Li W, Listernick R, Martin S, Morrison H, Pasmant E, Ratner N, Schorry E, Ullrich NJ, Viskochil D, Weiss B, Widemann BC, Zhu Y, Bakker A, Serra E.

Am J Med Genet A. 2018 May;176(5):1258-1269. doi: 10.1002/ajmg.a.38675.

15.

The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.

Higham CS, Dombi E, Rogiers A, Bhaumik S, Pans S, Connor SEJ, Miettinen M, Sciot R, Tirabosco R, Brems H, Baldwin A, Legius E, Widemann BC, Ferner RE.

Neuro Oncol. 2018 May 18;20(6):818-825. doi: 10.1093/neuonc/noy013.

16.

Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future.

Reilly KM, Kim A, Blakely J, Ferner RE, Gutmann DH, Legius E, Miettinen MM, Randall RL, Ratner N, Jumbé NL, Bakker A, Viskochil D, Widemann BC, Stewart DR.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx124. Review.

17.

Deaths from Medicines: A Systematic Analysis of Coroners' Reports to Prevent Future Deaths.

Ferner RE, Easton C, Cox AR.

Drug Saf. 2018 Jan;41(1):103-110. doi: 10.1007/s40264-017-0588-0.

PMID:
28808959
18.

Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA.

J Neuroophthalmol. 2017 Sep;37 Suppl 1:S23-S32. doi: 10.1097/WNO.0000000000000550. Review.

PMID:
28806346
19.

Unlicensed and off-label uses of medicines: definitions and clarification of terminology.

Aronson JK, Ferner RE.

Br J Clin Pharmacol. 2017 Dec;83(12):2615-2625. doi: 10.1111/bcp.13394. Epub 2017 Sep 26. Review.

20.

The toxicological significance of post-mortem drug concentrations in bile.

Ferner RE, Aronson JK.

Clin Toxicol (Phila). 2018 Jan;56(1):7-14. doi: 10.1080/15563650.2017.1339886. Epub 2017 Jul 6. Review.

PMID:
28681613
21.

Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas.

Byrne S, Connor S, Lascelles K, Siddiqui A, Hargrave D, Ferner RE.

J Neurooncol. 2017 Jul;133(3):609-614. doi: 10.1007/s11060-017-2475-z. Epub 2017 Jun 7.

22.

Aneurysms in neurofibromatosis type 2: Evidence for vasculopathy?

Afridi SK, Thomson S, Connor SEJ, Walsh DC, Ferner RE.

Am J Med Genet A. 2017 Jun;173(6):1562-1565. doi: 10.1002/ajmg.a.38221. Epub 2017 Apr 21.

PMID:
28429859
23.

The effect of post-injection 18F-FDG PET scanning time on texture analysis of peripheral nerve sheath tumours in neurofibromatosis-1.

Lovat E, Siddique M, Goh V, Ferner RE, Cook GJR, Warbey VS.

EJNMMI Res. 2017 Dec;7(1):35. doi: 10.1186/s13550-017-0282-3. Epub 2017 Apr 20.

24.

Biomarkers-A General Review.

Aronson JK, Ferner RE.

Curr Protoc Pharmacol. 2017 Mar 17;76:9.23.1-9.23.17. doi: 10.1002/cpph.19. Review.

PMID:
28306150
25.

A systematic review of the evidence for acute tolerance to alcohol - the "Mellanby effect".

Holland MG, Ferner RE.

Clin Toxicol (Phila). 2017 Jul;55(6):545-556. doi: 10.1080/15563650.2017.1296576. Epub 2017 Mar 9. Review.

PMID:
28277803
26.

Neurofibromatosis type 1.

Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ.

Nat Rev Dis Primers. 2017 Feb 23;3:17004. doi: 10.1038/nrdp.2017.4. Review.

PMID:
28230061
27.

Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.

Ferner RE, Thomas M, Mercer G, Williams V, Leschziner GD, Afridi SK, Golding JF.

Health Qual Life Outcomes. 2017 Feb 14;15(1):34. doi: 10.1186/s12955-017-0607-y.

28.

PCSK9 inhibitors for hypercholesterolaemia.

McGettigan P, Ferner RE.

BMJ. 2017 Jan 19;356:j188. doi: 10.1136/bmj.j188. No abstract available.

PMID:
28104607
29.

Manslaughter trials ignore systemic failures.

Ferner RE.

BMJ. 2016 Dec 30;355:i6630. doi: 10.1136/bmj.i6630. No abstract available.

PMID:
28039121
30.

Perceptions and Impact of Mandatory eLearning for Foundation Trainee Doctors: A Qualitative Evaluation.

Brooks HL, Pontefract SK, Vallance HK, Hirsch CA, Hughes E, Ferner RE, Marriott JF, Coleman JJ.

PLoS One. 2016 Dec 22;11(12):e0168558. doi: 10.1371/journal.pone.0168558. eCollection 2016.

31.
32.

Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation.

Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE, Halliday D, Jena R, Pretorius PM; UK NF2 Research group, Evans DG, McCabe MG, Parry A.

Neurooncol Pract. 2016 Dec;3(4):281-289. doi: 10.1093/nop/npv065. Epub 2016 Jan 7.

33.

Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort.

Morris KA, Golding JF, Blesing C, Evans DG, Ferner RE, Foweraker K, Halliday D, Jena R, McBain C, McCabe MG, Swampillai A, Warner N, Wilson S, Parry A, Afridi SK; UK NF2 research group.

J Neurooncol. 2017 Jan;131(1):117-124. doi: 10.1007/s11060-016-2276-9. Epub 2016 Oct 28.

PMID:
27796735
34.

Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.

Plotkin SR, Davis SD, Robertson KA, Akshintala S, Allen J, Fisher MJ, Blakeley JO, Widemann BC, Ferner RE, Marcus CL; REiNS International Collaboration.

Neurology. 2016 Aug 16;87(7 Suppl 1):S13-20. doi: 10.1212/WNL.0000000000002933.

35.

How similar are biosimilars?

Aronson JK, Ferner RE.

BMJ. 2016 May 17;353:i2721. doi: 10.1136/bmj.i2721. No abstract available.

PMID:
27188872
36.
37.

Authors' reply to Green and colleagues.

Ferner RE, Gogtay NJ.

BMJ. 2015 Dec 9;351:h6588. doi: 10.1136/bmj.h6588. No abstract available.

PMID:
26655828
38.

Mefloquine for malarial prophylaxis in military personnel.

Gogtay NJ, Ferner RE.

BMJ. 2015 Nov 3;351:h5797. doi: 10.1136/bmj.h5797. No abstract available.

PMID:
26534919
39.

Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology.

Ferner RE, Aronson JK.

Br J Clin Pharmacol. 2016 Jan;81(1):52-5. doi: 10.1111/bcp.12721. Epub 2015 Oct 22. Review.

40.

The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions.

Aronson JK, Ferner RE.

Br J Clin Pharmacol. 2016 Jan;81(1):56-61. doi: 10.1111/bcp.12706. Epub 2015 Oct 26. Review.

41.

Prevalence and clinical presentation of headache in a National Neurofibromatosis 1 Service and impact on quality of life.

Afridi SK, Leschziner GD, Ferner RE.

Am J Med Genet A. 2015 Oct;167A(10):2282-5. doi: 10.1002/ajmg.a.37186. Epub 2015 Jun 5.

PMID:
26044068
42.

A licence to cure.

Aronson JK, Ferner RE.

BMJ. 2015 Apr 1;350:h1723. doi: 10.1136/bmj.h1723. No abstract available.

PMID:
25834026
43.

Adverse drug reactions in dermatology.

Ferner RE.

Clin Exp Dermatol. 2015 Mar;40(2):105-9; quiz 109-10. doi: 10.1111/ced.12572. Epub 2015 Jan 27. Review.

PMID:
25622648
44.

Neurofibromatosis-related tumors: emerging biology and therapies.

Karajannis MA, Ferner RE.

Curr Opin Pediatr. 2015 Feb;27(1):26-33. doi: 10.1097/MOP.0000000000000169. Review.

45.

Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues.

Rauen KA, Huson SM, Burkitt-Wright E, Evans DG, Farschtschi S, Ferner RE, Gutmann DH, Hanemann CO, Kerr B, Legius E, Parada LF, Patton M, Peltonen J, Ratner N, Riccardi VM, van der Vaart T, Vikkula M, Viskochil DH, Zenker M, Upadhyaya M.

Am J Med Genet A. 2015 Jan;167A(1):1-10. doi: 10.1002/ajmg.a.36793. Epub 2014 Nov 12.

46.

A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation?

Barber J, McKeever TM, McDowell SE, Clayton JA, Ferner RE, Gordon RD, Stowasser M, O'Shaughnessy KM, Hall IP, Glover M.

Br J Clin Pharmacol. 2015 Apr;79(4):566-77. doi: 10.1111/bcp.12499.

47.

Systemic toxicity related to metal hip prostheses.

Bradberry SM, Wilkinson JM, Ferner RE.

Clin Toxicol (Phila). 2014 Sep-Oct;52(8):837-47. doi: 10.3109/15563650.2014.944977. Epub 2014 Aug 16. Review.

PMID:
25132471
48.

Temporal and other factors that influence the time doctors take to prescribe using an electronic prescribing system.

Coleman JJ, Hodson J, Thomas SK, Brooks HL, Ferner RE.

J Am Med Inform Assoc. 2015 Jan;22(1):206-12. doi: 10.1136/amiajnl-2014-002822. Epub 2014 Jul 29.

49.

Fundamentals of lung auscultation.

Coleman JJ, Ferner RE.

N Engl J Med. 2014 May 22;370(21):2052. doi: 10.1056/NEJMc1403766. No abstract available.

PMID:
24849096
50.

Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma.

Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, D'Agostino McGowan L, Liu GT.

Ann Neurol. 2014 May;75(5):799-800. doi: 10.1002/ana.24157. Epub 2014 May 14. No abstract available.

PMID:
24740685

Supplemental Content

Loading ...
Support Center